Background Probiotic supplementation significantly reduces the risk of necrotising enterocolitis (NEC) and all cause mortality in preterm neonates. Independent quality assessment is important before introducing routine probiotic supplementation in this cohort. Aim To assess product quality, and confirm that Bifidobacterium breve (B. breve) M-16V supplementation will increase fecal B. breve counts without adverse effects. Methods and Participants Strain identity (16S rRNA gene sequencing), viability over 2 year shelf-life were confirmed, and microbial contamination of the product was ruled out. In a controlled trial preterm neonates (Gestation <33 weeks) ready to commence or on feeds for <12 hours were randomly allocated to either B. breve M-16V (3×109 cfu/day) or placebo (dextrin) supplementation until the corrected age 37 weeks. Stool samples were collected before (S1) and after 3 weeks of supplementation (S2) for studying fecal B. breve levels using quantitative PCR (Primary outcome). Secondary outcomes included total fecal bifidobacteria and NEC≥Stage II. Categorical and continuous outcomes were analysed using Chi-square and Mann-Whitney tests, and McNemar and Wilcoxon signed-rank tests for paired comparisons. Results A total of 159 neonates (Probiotic: 79, Placebo: 80) were enrolled. Maternal and neonatal demographic characteristics were comparable between the groups. The proportion of neonates with detectable B. breve increased significantly post intervention: Placebo: [S1:2/66 (3%), S2: 25/66 (38%), p<0.001] Probiotic: [S1: 29/74 (40%), S2: 67/74 (91%), p<0.001]. Median S1 B. breve counts in both groups were below detection (<4.7 log cells.g？1), increasing significantly in S2 for the probiotic group (log 8.6) while remaining <4.7 log in the control group (p<0.001). There were no adverse effects including probiotic sepsis and no deaths. NEC≥Stage II occurred in only 1 neonate (placebo group). Conclusion B. breve M-16V is a suitable probiotic strain for routine use in preterm neonates. Trial Registration Australia New Zealand Clinical Trial Registry ACTRN 12609000374268
References
[1]
Neu J, Walker WA (2011) Necrotizing enterocolitis. NEJ Med 364: 255–264. doi: 10.1056/nejmra1005408
Jain L (2013) Necrotizing enterocolitis prevention: art or science? Clin Perinatol 40(1): xiii–xv doi: 10.1016/j.clp.2013.01.002.
[4]
FAO/WHO Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. 2001. Available: http://www.who.int/foodsafety/publicatio？ns/fs_management/en/probiotics.pdf. Accessed 2012 June 4.
[5]
Bermudez-Brito M, Plaza-Díaz J, Mu？oz-Quezada S, Gómez-Llorente C, Gil A (2012) Probiotic mechanisms of action. Ann Nutr Metab 61(2): 160–74. doi: 10.1159/000342079
[6]
Claud EC, Walker WA (2008) Bacterial colonization, probiotics, and necrotizing enterocolitis. J Clin Gastroenterol 42 Suppl 2: S46–52. doi: 10.1097/mcg.0b013e31815a57a8
[7]
Ganguli K, Walker WA (2012) Treatment of necrotizing enterocolitis with probiotics. Gastroenterol Clin N Am 41: 733–746. doi: 10.1016/j.gtc.2012.08.004
[8]
Martin CR, Walker WA (2008) Probiotics: role in pathophysiology and prevention in necrotizing enterocolitis. Semin Perinatol 32(2): 127–37. doi: 10.1053/j.semperi.2008.01.006
[9]
Alfaleh K, Anabrees J, Bassler D, Al-Kharfi T (2011) Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev Mar 16(3): CD005496. doi: 10.1002/14651858.cd005496.pub3
[10]
Deshpande G, Rao S, Patole S, Bulsara M (2010) Updated meta analysis of probiotics for preventing necrotising enterocolitis in preterm neonates. Pediatrics 125(5): 921–30. doi: 10.1542/peds.2009-1301
[11]
Wang Q, Dong J, Zhu Y (2012) Probiotic supplement reduces risk of necrotizing enterocolitis and mortality in preterm very low-birth-weight infants: an updated meta-analysis of 20 randomized, controlled trials. J Pediatric Surg 47: 241–248. doi: 10.1016/j.jpedsurg.2011.09.064
[12]
Deshpande GC, Rao SC, Keil AD, Patole SK (2011) Evidence-based guidelines for use of probiotics in preterm neonates. BMC Med Aug 2;9: 92 doi: 10.1186/1741-7015-9-92.
[13]
Tarnow-Mordi WO, Wilkinson D, Trivedi A, Brok J (2010) Probiotics reduce all-cause mortality and necrotizing enterocolitis: it is time to change practice. Pediatr 125: 1068–1070. doi: 10.1542/peds.2009-2151
[14]
Barrington KJ (2011) Review: probiotics prevented necrotising enterocolitis and reduced mortality in pretneonates. Arch Dis Child Educ Pract Ed 96: 199. doi: 10.1136/adc.2011.214569
[15]
Swanson JR (2013) Necrotizing enterocolitis: is it time for zero tolerance? J Perinatol 33: 1–2. doi: 10.1038/jp.2012.122
[16]
Janvier A, Lantos J, Barrington K (2012) The politics of probiotics: probiotics, necrotizing enterocolitis and the ethics of neonatal research. Acta Paediatr 102: 116–118. doi: 10.1111/apa.12083
[17]
Umezaki H, Shinohara K, Satoh Y, Shoji H, Satoh H, et al. (2010) Bifidobacteria prevents preterm infants from developing infection and sepsis. Int J Probiotics Prebiotics 5(1): 33–36.
[18]
Satoh Y, Koichi S, Hikaru U, Shoji H, Satoh H, et al. (2007) Bifidobacteria prevents necrotising enterocolitis and infection in preterm infants. Int J Probiotics Prebiotics 2(2/3): 149–54.
[19]
Li Y, Shimizu T, Hosaka A, Kaneko N, Ohtsuka Y, et al. (2004) Effects of Bifidobacterium breve supplementation on intestinal flora of low birth weight infants. Pediatr Int 46(5): 509–15. doi: 10.1111/j.1442-200x.2004.01953.x
[20]
Wang C, Shoji H, Sato H, Nagata S, Ohtsuka Y, et al. (2007) Effects of oral administration of Bifidobacterium breve on fecal lactic acid and short-chain fatty acids in low birth weight infants. J Pediatr Gastroenterol Nutr 44(2): 252–7. doi: 10.1097/01.mpg.0000252184.89922.5f
[21]
Fujii T, Ohtsuka Y, Lee T, Kudo T, Shoji H, et al. (2006) Bifidobacterium breve enhances transforming growth factor beta1 signaling by regulating Smad7 expression in preterm infants. J Pediatr Gastroenterol Nutr 43(1): 83–8. doi: 10.1097/01.mpg.0000228100.04702.f8
[22]
Abe F, Yaeshima T, Iwatsuki K (2009) Safety evaluation of two probiotic bifidobacterial strains, Bifidobacterium breve M-16V and Bifidobacterium infantis M-63, by oral toxicity tests using rats. Bioscience Microflora 28(1): 7–15.
[23]
Abe F, Muto M, Yaeshima T, Iwatsuki K, Aihara H, et al. (2010) Safety evaluation of probiotic bifidobacteria by analysis of mucin degradation activity and translocation ability. Anaerobe 16(2): 131–6.
[24]
Weisburg WG, Barns SM, Pelletier DA, Lane DJ (1991) 16S ribosomal DNA amplification for phylogenetic study. J Bacteriol 173: 697–703.
[25]
M？tt？ J, van Hoek AHAM, Domig KJ, Saarela M, Florez AB, et al. (2007) Susceptibility of human and probiotic Bifidobacterium spp. to selected antibiotics as determined by the Etest method. Int Dairy J 17: 1123–1131. doi: 10.1016/j.idairyj.2007.01.008
[26]
Walsh MC, Kliegman RM (1986) Necrotising enterocolitis: treatment based on staging criteria. Pediatr Clin North Am 33: 179–201.
[27]
Locascio M, Holgado AP, Perdigón G, Oliver G (2001) Enteric bifidobacteria: isolation from human infants and challenge studies in mice. Can J Microbiol 47(11): 1048–52. doi: 10.1139/w01-112
[28]
Matsuki T, Watanabe K, Tanaka R (2003) Genus- and species-specific PCR primers for the detection and identification of bifidobacteria. Current Issues Intestinal Microbiology 4(2): 61–9. doi: 10.1111/j.1574-6968.1998.tb13216.x
[29]
Matsuki T, Watanabe K, Tanaka R, Fukuda M, Oyaizu H (1999) Distribution of bifidobacterial species in human intestinal microflora examined with 16S rRNA-gene-targeted species-specific primers. Appl Environ Microbiol 65(10): 4506–4512.
[30]
Schouten B, van Esch B, Hifman GA, van Doorn S, Knol J, et al. (2009) Cow milk allergy symptoms are reduced in mice fed dietary synbiotics during oral sensitization with whey. J Nutr 139(7): 1398–1403. doi: 10.3945/jn.109.108514
[31]
Australian Government National Health and Medical Research Council. Joint NHMRC/AVCC Statement and Guidelines on Research Practice (1997). Available: http://www.nhmrc.gov.au/guidelines/publi？cations/r0024. Accessed 2014 January 17.
[32]
Moher D, Schulz KF, Altman D (2001) CONSORT Group (Consolidated Standards of Reporting Trials).The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 285(15): 1987–91. doi: 10.1001/jama.285.15.1987
[33]
Williams AF (1997) Role of feeding in necrotizing enterocolitis. Semin Neonatol 1997;2: 263–71. doi: 10.1016/s1084-2756(97)80033-4
[34]
Kitajima H, Sumida Y, Tanaka R, Yuki N, Takayama H (1997) Early administration of Bifidobacterium breve to preterm infants: randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 76: F101–107. doi: 10.1136/fn.76.2.f101
[35]
Mikami K, Kimura M, Takahashi H (2012) Influence of maternal bifidobacteria on the development of gut bifidobacteria in infants. Pharmaceuticals 5: 629–642 doi:10.3390/ph5060629.
[36]
Martin R, Jimenez E, Heilig H, Fernandez L, Marin ML, et al. (2009) Isolation of bifidobacteria from breast milk and assessment of the bifidobacterial population by PCR-denaturing gradient gel electrophoresis and quantitative real-time PCR. Appl Environ Microbiol 75: 965–969. doi: 10.1128/aem.02063-08
[37]
Canani RB, Di Costanzo M, Leone L, Pedata M, Meli R, et al. (2011) Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol 17(12): 1519–1528. doi: 10.3748/wjg.v17.i12.1519
[38]
Layden BT, Angueira AR, Brodsky M, Durai V, Lowe WL Jr (2013) Short chain fatty acids and their receptors: new metabolic targets. Transl Res 161(3): 131–40. doi: 10.1016/j.trsl.2012.10.007
[39]
Namachivayam K, Blanco CL, MohanKumar K, Jagadeeswaran R, Vasquez M, et al. (2013) Smad7 inhibits autocrine expression of TGF-β2 in intestinal epithelial cells in baboon necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol 304(2): G167–80. doi: 10.1152/ajpgi.00141.2012
[40]
Shanahan F (2012) A commentary on the safety of probiotics. Gastroenterol Clin N Am 41: 869–876. doi: 10.1016/j.gtc.2012.08.006
[41]
Seale JV, Millar M (2013) Probiotics: a new frontier for infection control. J Hosp Infect Feb 13 doi:pii: S0195-6701(13)00035-2. 10.1016/j.jhin.2013.01.005.
